FGFR2 Fusion is an inclusion criterion in 10 clinical trials for cholangiocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain FGFR2 Fusion and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 2 are phase 3 (2 open) [5].

Infigratinib and pemigatinib have evidence of efficacy in patients with FGFR2 Fusion in cholangiocarcinoma [5].

FGFR2 Fusion is an inclusion criterion in 24 clinical trials for malignant solid tumor, of which 18 are open and 6 are closed. Of the trials that contain FGFR2 Fusion and malignant solid tumor as inclusion criteria, 7 are phase 1 (2 open), 6 are phase 1/phase 2 (5 open), 10 are phase 2 (10 open), and 1 is phase 4 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 10 clinical trials for urothelial carcinoma, of which 10 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 5 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain FGFR2 Fusion and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 5 are open and 2 are closed. Of the trials that contain FGFR2 Fusion and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 5 are phase 2 (4 open) [5].

FGFR2 Fusion is an inclusion criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain FGFR2 Fusion and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 4 clinical trials for intrahepatic cholangiocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 4 clinical trials for gastric carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

FGFR2 Fusion is an inclusion criterion in 4 clinical trials for cancer, of which 1 is open and 3 are closed. Of the trials that contain FGFR2 Fusion and cancer as inclusion criteria, 4 are phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FGFR2 Fusion is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain FGFR2 Fusion and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Fusion and bladder carcinoma as inclusion criteria, 3 are phase 1 (2 open) [5].

FGFR2 Fusion is an inclusion criterion in 3 clinical trials for sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Fusion and sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FGFR2 Fusion is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FGFR2 Fusion is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Fusion and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Fusion and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Fusion and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Fusion and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Fusion and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 Fusion is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Fusion and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Fusion and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Fusion and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Fusion and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for lymphocytic neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and lymphocytic neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Fusion and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Fusion and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for non-muscle invasive bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and non-muscle invasive bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for perihilar intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and perihilar intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FGFR2 Fusion is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Fusion and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].